Page last updated: 2024-12-10
diclosulam
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
diclosulam: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 3081304 |
| CHEMBL ID | 1873575 |
| CHEBI ID | 81984 |
| SCHEMBL ID | 116344 |
| MeSH ID | M0372199 |
Synonyms (34)
| Synonym |
|---|
| 6x5do0i08z , |
| unii-6x5do0i08z |
| NCGC00163839-01 |
| n-(2,6-dichlorophenyl)-5-ethoxy-7-fluoro[1,2,4]triazolo[1,5-c]pyrimidine-2-sulfonamide |
| diclosulam |
| 145701-21-9 |
| (1,2,4)triazolo(1,5-c)pyrimidine-2-sulfonamide, n-(2,6-dichlorophenyl)-5-ethoxy-7-fluoro- |
| diclosulam [iso] |
| n-(2,6-dichlorophenyl)-5-ethoxy-7-fluoro-(1,2,4)triazolo(1,5-c)pyrimidine-2-sulfonamide |
| NCGC00163839-02 |
| n-(2,6-dichlorophenyl)-5-ethoxy-7-fluoro-[1,2,4]triazolo[1,5-c]pyrimidine-2-sulfonamide |
| NCGC00163839-03 |
| strongarm |
| n-(2,6-dichlorophenyl)-5-ethoxy-7-fluoro(1,2,4)triazolo(1,5-c)pyrimidine-2-sulfonamide |
| C18821 |
| dtxsid4034528 , |
| tox21_300765 |
| cas-145701-21-9 |
| dtxcid2014528 |
| NCGC00254669-01 |
| FT-0631172 |
| AKOS015899984 |
| diclosulam [mi] |
| 2',6'-dichloro-5-ethoxy-7-fluoro(1,2,4)triazolo(1,5-c)pyrimidine-2-sulfonanilide |
| xde-564 |
| SCHEMBL116344 |
| CHEBI:81984 , |
| CHEMBL1873575 |
| [1,2,4]triazolo[1,5-c]pyrimidine-2-sulfonamide, n-(2,6-dichlorophenyl)-5-ethoxy-7-fluoro- |
| J-008139 |
| mfcd04972567 |
| Q27155672 |
| spider (herbicide); strongarm; xde 564 |
| diclosulam 100 microg/ml in acetonitrile |
Research Excerpts
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| sulfonamide | An amide of a sulfonic acid RS(=O)2NR'2. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (13)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 61.1306 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 28.9240 | 0.0007 | 14.5928 | 83.7951 | AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 46.1217 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID743036 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 48.5577 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 48.5577 | 0.0010 | 22.6508 | 76.6163 | AID1224838 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 36.7537 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 39.7824 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1259401 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 44.8032 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 2.7536 | 0.0010 | 24.5048 | 61.6448 | AID743215 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 13.4987 | 0.0010 | 19.4141 | 70.9645 | AID588536; AID743094; AID743140 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 21.8724 | 0.0237 | 23.2282 | 63.5986 | AID743223 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 24.3365 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 61.1306 | 0.0006 | 27.2152 | 1,122.0200 | AID651741 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 54.30
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (54.30) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||